XIENCE V PROMUS Stent

Related by string. * Xience : XIENCE V demonstrated . XIENCE V Everolimus Eluting . XIENCE V drug eluting . XIENCE V Stent System / VD . Vs . vs . VS : b v * . V CAST Music . Microsoft Hyper V . overturn Roe v. Wade / Promus : PROMUS XIENCE V . PROMUS Element Everolimus Eluting . Boston Scientific Promus / stenting . Stents . Stenting : drug coated stents . stents inserted . Endeavor stent * *

Related by context. Frequent words. (Click for all words.) 69 XIENCE V vs. 67 target lesion revascularization 67 CYPHER ® Stent 67 TAXUS Express 67 vertebral fracture 66 serum phosphorus 66 thromboembolic events 66 TAXUS stent 66 plus gemcitabine 65 plus prednisone 65 thromboembolism 65 virologic response 65 cardiovascular hospitalization 65 composite endpoint 65 virologic failure 65 coronary revascularization 65 secondary efficacy endpoints 65 Coronary Stent 64 noninferiority 64 PROMACTA 64 sustained virologic response 64 active comparator 64 Enoxaparin 64 decitabine 64 mg QD 64 TAXUS 64 TORISEL 64 tumor lysis syndrome 64 myocardial infarction MI 64 Pivotal Phase III 64 peginterferon alfa 2a 64 XELOX 63 myocardial infarction stroke 63 achieved statistical significance 63 annualized relapse 63 Acute Myocardial Infarction 63 Amrubicin 63 cytogenetic response 63 Pioglitazone 63 ADHF 63 azacitidine 63 Lenalidomide 63 stent restenosis 63 Pivotal Trial 63 fondaparinux 63 ADAS cog 63 Navelbine 63 Pivotal Phase 63 rosuvastatin 63 Stent System 63 T2DM 63 HbA1c levels 63 Chronic Hepatitis C 63 tamsulosin 63 stable angina 62 LVEF 62 bosentan 62 enalapril 62 mg kg dose 62 sensitivity specificity 62 peginterferon alfa 2b 62 confidence interval #.#-#.# 62 evaluable 62 carotid artery stenting 62 stent implantation 62 febrile neutropenia 62 target vessel revascularization 62 estimated glomerular filtration 62 metastatic renal cell carcinoma 62 elagolix 62 Rivaroxaban 62 acute coronary syndromes 62 dacarbazine 62 placebo controlled clinical 62 lipid lowering drugs 62 XGEVA 62 angiotensin converting enzyme inhibitors 62 relapsed multiple myeloma 62 statistically significant p = 62 discontinuations due 62 cerebrovascular events 62 renal impairment 62 SPIRIT III 61 mg BID 61 carotid stenting 61 Secondary endpoints 61 Sirolimus 61 plus methotrexate 61 FOLFIRI 61 thrombotic events 61 TIMI 61 D dimer 61 myocardial infarctions 61 left ventricular dysfunction 61 CYPHER R Stent 61 endarterectomy 61 CORTOSS 61 C Reactive Protein 61 Myocardial Infarction 61 adalimumab 61 placebo p =

Back to home page